Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | CTSV | O60911 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | CTSC | P53634 | 1/20 | 0.36 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.33 |
| ▸ | KLK7 | P49862 | 6/20 | 0.33 |
| ▸ | KLK5 | Q9Y337 | 4/20 | 0.33 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL438380 | 0.73 | L3MBTL1 (0.44) | BCHECTSVCTSLCTSBCTSS | |
| SCHEMBL18040923 | 0.69 | BCHE (0.43) | BCHECTSVCTSLCTSBCTSS | |
| SCHEMBL18580306 | 0.68 | SMN1; SMN2 (0.43) | BCHECTSVCTSLCTSBCTSS | |
| SCHEMBL18986859 | 0.67 | PDPK1 (0.45) | CTSVCTSLCTSBCTSSCTSK | |
| SCHEMBL21196194 | 0.66 | CTSL (0.40) | BCHECTSVCTSLCTSBCTSS | |
| SCHEMBL30379975 | 0.66 | CTSL (0.40) | BCHECTSVCTSLCTSBCTSS | |
| SCHEMBL2940477 | 0.66 | CTSL (0.57) | BCHECTSLCTSBCTSKGRIN2B | |
| SCHEMBL21195882 | 0.65 | CTSL (0.40) | BCHECTSVCTSLCTSBCTSS | |
| SCHEMBL21195880 | 0.65 | CTSL (0.40) | BCHECTSVCTSLCTSBCTSS | |
| SCHEMBL2456870 | 0.65 | SMN1; SMN2 (0.40) | BCHECTSVCTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270354-A1 | Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof | SANOFI-AVENTIS (FR) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270354-A1 | Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof | HPSE, HAAO, HEXD | BCHE 1409/4885CTSV 1027/4885CTSL 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.